7 results
Primary objectives* To assess the tolerability of regorafenib combined with paclitaxel.Secondary objectives* To assess the effect of regorafenib on uptake of paclitaxel in OGC metastases.* To assess the effect of regorafenib on regorafenib targets…
This protocol is designed to determine the safety, tolerability, and efficacy of SGI-110 in combination with irinotecan in previously treated patients with metastatic colorectal cancer who progressed on irinotecan.
The objective of this study is to evaluate efficacy and safety of regorafenib in patients with HCC who have progressed after sorafenib.
To evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapies.The primary efficacy endpoint of this study is * Overall survivalThe secondary efficacy endpoints of this…
Primary Objective:* The primary objective is to demonstrate the efficacy of avapritinib based on progression-free survival (PFS) determined by central radiological assessment per modified Response Evaluation Criteria in Solid Tumors (mRECIST),…
The primary objective of the study is to compare the efficacy of brigatinib to that of crizotinib in ALK+ locally advanced or metastatic NSCLC patients naive to ALK inhibitors, as evidenced by PFS.The secondary objectives of the study are:1. To…
Primary objective:Part 1: To determine the safety, tolerability, and RP2D of a daily dosing schedule (induction) of GSK3745417 Part 2: To evaluate clinical efficacy following the daily dosing *induction* period of GSK3745417 in participants with…